Career Enhancement Program
Career Enhancement Program
批准号:
10005149
负责人:
Timothy Charles Thompson
金额:
$15.41万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-02 至 2023-08-31
关键词:
Applications GrantsAreaAwardCancer BiologyCancer CenterCancer Research ProjectClinicalCommunicationCritiquesDegree programDevelopmentDisciplineDoctor of PhilosophyDoctor&aposs DegreeEducational process of instructingEnsureEvaluationFacultyFundingGenitourinary systemGoalsGrant ReviewGuidelinesHumanIndividualInstitutionK-Series Research Career ProgramsLaboratoriesLaboratory ScientistsLeadershipMalignant neoplasm of prostateMedical OncologistMentorsMentorshipMethodsMinorityModificationPeer Review GrantsPhysiciansPilot ProjectsPopulationPrincipal InvestigatorProcessProgram EvaluationProgram Research Project GrantsPublicationsRecordsReportingReproduction sporesResearchResearch PersonnelResearch Project GrantsSchoolsScienceScientistSeriesStatistical Data InterpretationTalentsTechnical ExpertiseTechniquesTexasTrainingTranslational ResearchUnited States National Institutes of HealthUniversitiesWomanWorkanticancer researchbasecareereducational atmosphereexperienceinnovationinterestmemberorganizational structureprogramsrecruitresponseskillssuccesstranslational studyweb site
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY (Career Enhancement Program)
The goal of the Career Enhancement Program (CEP) of the MD Anderson Cancer Center Prostate Cancer
SPORE (Prostate Cancer SPORE) is to develop a cadre of investigators dedicated to translational studies of
human prostate cancer. It is directed by Dr. Gary E. Gallick and co-directed by Dr. Christopher J. Logothetis.
The program will: 1) recruit innovative entry-level scientists to the Prostate Cancer SPORE to enhance the
overall translational research capability of the SPORE and bring new techniques and talent to our program; 2)
help these individuals develop the intellectual and technical skills required to be productive investigators in
translational prostate cancer research; 3) teach these individuals basic principles of cancer biology not
commonly included in clinical training or doctoral degree programs; and 4) guide the entry-level scientists in
the development of competitive grant proposals in the area of translational prostate cancer research. The
unique educational environment at MD Anderson will ensure that these goals will be met. At least two Career
Enhancement awardees will be selected annually during the active funding period from qualified candidates
within and outside MD Anderson who respond to a SPORE solicitation based on the defined criteria. Special
emphasis will be placed on recruiting qualified women and members of minority populations whenever
possible. In response to the previous critique, Dr. Logothetis will be actively involved in recruiting qualified
physician/scientists to increase the number of MDs obtaining CEPs. Mentorship training will include principles
of cancer biology, scientific methods, statistical analysis, biomedical communications, and strategies
necessary to become successful in translational prostate cancer research. Several courses in The University of
Texas Graduate School of Biomedical Sciences at Houston that encompass these disciplines are available to
CEP recipients. The CEP recipients will be evaluated annually, and the selection process and training will be
modified when appropriate. In addition, “upward” evaluation by recipients to their mentors will also occur
annually, with modifications to the program made, as necessary, in response to input of CEP recipients (see
Appendix “CEP Pilot Project Review Form” and “CEP Evaluation Form” for evaluation criteria).
Nine Career Development awards (now Career Enhancement awards) have been funded by the Prostate
Cancer SPORE. Investigators receiving CDP awards wrote 53 publications. A total of 25 externally reviewed
grant applications were funded. Of note, Dr. Hui-Kuan Lin, a CDP awardee, will submit a Developmental
Research Program (DRP) project to the SPORE, reflecting the synergistic relationship between the CEP and
DRP mechanisms. Dr. Ana Aparicio, genitourinary medical oncologist, is a CEP awardee.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting Non-Canonical STING Signaling to Treat SPOP Mutant Castration-Resistant Prostate Cancer
-
批准号:10709358
-
项目类别:
-
资助金额:$66.83万
-
财政年份:2023
-
负责人:Timothy Charles Thompson
-
依托单位:
Targeting Androgen Receptor and PARP for Synthetic Lethality in CRPC
-
批准号:10005152
-
项目类别:
-
资助金额:$28.9万
-
财政年份:2009
-
负责人:Timothy Charles Thompson
-
依托单位:
Targeting Androgen Receptor and PARP for Synthetic Lethality in CRPC
-
批准号:10706700
-
项目类别:
-
资助金额:$30.91万
-
财政年份:2009
-
负责人:Timothy Charles Thompson
-
依托单位:
GLIPR1-ATM Protein Therapy for Prostate Cancer
-
批准号:7743202
-
项目类别:
-
资助金额:$25.43万
-
财政年份:2009
-
负责人:Timothy Charles Thompson
-
依托单位:
Developmental Research Program
-
批准号:8999526
-
项目类别:
-
资助金额:$7.52万
-
财政年份:2009
-
负责人:Timothy Charles Thompson
-
依托单位:
Developmental Research Program
-
批准号:7743213
-
项目类别:
-
资助金额:$13.95万
-
财政年份:2009
-
负责人:Timothy Charles Thompson
-
依托单位:
Developmental Research Program
-
批准号:10005148
-
项目类别:
-
资助金额:$15.41万
-
财政年份:2009
-
负责人:Timothy Charles Thompson
-
依托单位:
Targeting Androgen Receptor and PARP for Synthetic Lethality in CRPC
-
批准号:8999530
-
项目类别:
-
资助金额:$32.88万
-
财政年份:2009
-
负责人:Timothy Charles Thompson
-
依托单位:
GENE THERAPY FOR PROSTATE CANCER
-
批准号:6316543
-
项目类别:
-
资助金额:$17.47万
-
财政年份:2000
-
负责人:Timothy Charles Thompson
-
依托单位:
GENE THERAPY FOR PROSTATE CANCER
-
批准号:6217437
-
项目类别:
-
资助金额:$17.47万
-
财政年份:1999
-
负责人:Timothy Charles Thompson
-
依托单位:
GENE THERAPY FOR PROSTATE CANCER
-
批准号:6296053
-
项目类别:
-
资助金额:$17.47万
-
财政年份:1999
-
负责人:Timothy Charles Thompson
-
依托单位:
GENE THERAPY FOR PROSTATE CANCER
-
批准号:6296065
-
项目类别:
-
资助金额:$17.47万
-
财政年份:1999
-
负责人:Timothy Charles Thompson
-
依托单位:
GENE THERAPY FOR PROSTATE CANCER
-
批准号:6102834
-
项目类别:
-
资助金额:$17.47万
-
财政年份:1999
-
负责人:Timothy Charles Thompson
-
依托单位:
GENE THERAPY FOR PROSTATE CANCER
-
批准号:6269589
-
项目类别:
-
资助金额:$18.08万
-
财政年份:1998
-
负责人:Timothy Charles Thompson
-
依托单位:
GENE THERAPY FOR PROSTATE CANCER
-
批准号:6296077
-
项目类别:
-
资助金额:$18.08万
-
财政年份:1998
-
负责人:Timothy Charles Thompson
-
依托单位:
GENE THERAPY FOR PROSTATE CANCER
-
批准号:6237333
-
项目类别:
-
资助金额:$17.68万
-
财政年份:1997
-
负责人:Timothy Charles Thompson
-
依托单位:
MECHANISMS OF METASTASIS IN EXPERIMENTAL PROSTATE CANCER
-
批准号:2112847
-
项目类别:
-
资助金额:$24.42万
-
财政年份:1995
-
负责人:Timothy Charles Thompson
-
依托单位:
MECHANISMS OF METASTASIS IN EXPERIMENTAL PROSTATE CANCER
-
批准号:2112846
-
项目类别:
-
资助金额:$20.84万
-
财政年份:1995
-
负责人:Timothy Charles Thompson
-
依托单位:
MECHANISMS OF METASTASIS IN EXPERIMENTAL PROSTATE CANCER
-
批准号:2429874
-
项目类别:
-
资助金额:$25.4万
-
财政年份:1995
-
负责人:Timothy Charles Thompson
-
依托单位:
Mechanisms of Metastasis in Experimental Prostate Cancer
-
批准号:7095542
-
项目类别:
-
资助金额:$29.77万
-
财政年份:1995
-
负责人:Timothy Charles Thompson
-
依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
-
批准号:2021JJ40433
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:孙磊
-
依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
-
批准号:32001603
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:段真珍
-
依托单位:
AREA国际经济模型的移植.改进和应用
-
批准号:18870435
-
项目类别:面上项目
-
资助金额:2.0万元
-
批准年份:1988
-
负责人:史树中
-
依托单位: